Commercial rights to HYALGAN transitioned from Sanofi back to Fidia, the brand's owner and manufacturer Wholly-owned subsidiary, Fidia Pharma USA Inc., engages Interpace BioPharma, LLC. to handle distribution and promotional support Fidia Farmaceutici S.p.A. ("Fidia") announced today that it has assumed responsibility for distributing and promoting the osteoarthritis (OA) treatment, HYALGAN (sodium hyaluronate), in the United States through its wholly-owned subsidiary, Fidia Pharma USA Inc. (